2.5.1.21 Acidosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9503410&form=6&db=m [Inhibitory action of natural compounds of microbial origin on cholesterol metabolism] therapeutic application,unassigned 1,0 2.5.1.21 Acquired Immunodeficiency Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10669567&form=6&db=m Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Acute Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22949548&form=6&db=m Streptococcal M1 protein triggers farnesyltransferase-dependent formation of CXC chemokines in alveolar macrophages and neutrophil infiltration in the lung. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.5.1.21 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9770500&form=6&db=m A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 2.5.1.21 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12663718&form=6&db=m Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,2,4 2.5.1.21 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17348444&form=6&db=m Expression of PTEN and FHIT is involved in regulating the balance between apoptosis and proliferation in lung carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 2.5.1.21 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22272079&form=6&db=m Enhanced Antiproliferative and Apoptotic Response of HT-29 Adenocarcinoma Cells to Combination of Photoactivated Hypericin and Farnesyltransferase Inhibitor Manumycin A. ongoing research,therapeutic application,unassigned 2,3,0 2.5.1.21 Adenocarcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31677963&form=6&db=m The diagnostic utility of zinc E-box 1 (ZEB1) transcription factor for identification of pulmonary sarcomatoid carcinoma in cytologic and surgical specimens. diagnostic usage,therapeutic application,unassigned 3,2,0 2.5.1.21 Adenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10607742&form=6&db=m Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 2.5.1.21 Adenoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33307558&form=6&db=m Role of the Mevalonate Pathway in Adrenocortical Tumorigenesis. causal interaction,ongoing research,unassigned 3,1,0 2.5.1.21 Adrenocortical Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34353633&form=6&db=m Identification of novel lipid metabolic biomarkers associated with poor adrenocortical carcinoma prognosis using integrated bioinformatics. causal interaction,diagnostic usage,unassigned 3,4,0 2.5.1.21 Alcohol-Related Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14601350&form=6&db=m The FIP study: a randomised, controlled trial of screening and recognition of psychiatric disorders. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,2,0 2.5.1.21 Alzheimer Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24136196&form=6&db=m Farnesyltransferase haplodeficiency reduces neuropathology and rescues cognitive function in a mouse model of Alzheimer disease. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,2,0 2.5.1.21 Anemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18032975&form=6&db=m New and old treatment modalities in primary myelofibrosis. therapeutic application,unassigned 4,0 2.5.1.21 Arrhythmias, Cardiac http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15037817&form=6&db=m Effects of sasanquasaponin on ischemia and reperfusion injury in mouse hearts. causal interaction,therapeutic application,unassigned 3,2,0 2.5.1.21 Arrhythmogenic Right Ventricular Dysplasia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34374184&form=6&db=m Chemical Genetics Reveals a Role of Squalene Synthase in TGF? Signaling and Cardiomyogenesis. therapeutic application,unassigned 1,0 2.5.1.21 Arthritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15240720&form=6&db=m Inhibition of farnesyltransferase prevents collagen-induced arthritis by down-regulation of inflammatory gene expression through suppression of p21(ras)-dependent NF-kappaB activation. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 2.5.1.21 Arthritis, Experimental http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15240720&form=6&db=m Inhibition of farnesyltransferase prevents collagen-induced arthritis by down-regulation of inflammatory gene expression through suppression of p21(ras)-dependent NF-kappaB activation. causal interaction,ongoing research,therapeutic application,unassigned 4,4,3,0 2.5.1.21 Arthritis, Rheumatoid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27699656&form=6&db=m Dichotomous versus semi-quantitative scoring of ultrasound joint inflammation in rheumatoid arthritis using novel individualized joint selection methods. ongoing research,unassigned 3,0 2.5.1.21 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24582968&form=6&db=m Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26119637&form=6&db=m Exploring the potential of sequential simulation. causal interaction,unassigned 1,0 2.5.1.21 Asthma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29703864&form=6&db=m Farnesyltransferase Inhibition Exacerbates Eosinophilic Inflammation and Airway Hyperreactivity in Mice with Experimental Asthma: The Complex Roles of Ras GTPase and Farnesylpyrophosphate in Type 2 Allergic Inflammation. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 2.5.1.21 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10667233&form=6&db=m The farnesyltransferase inhibitor L-744,832 inhibits the growth of astrocytomas through a combination of antiproliferative, antiangiogenic, and proapoptotic activities. therapeutic application,unassigned 2,0 2.5.1.21 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11213969&form=6&db=m Establishment and characterization of a novel malignant astrocytoma cell line derived from a tumor removed in a patient with neurofibromatosis type 1. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Astrocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12622448&form=6&db=m In vitro and in vivo growth inhibition of human malignant astrocytoma cells by the farnesyltransferase inhibitor B1620. diagnostic usage,ongoing research,unassigned 3,4,0 2.5.1.21 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17363690&form=6&db=m Farnesyltransferase inhibitor, manumycin a, prevents atherosclerosis development and reduces oxidative stress in apolipoprotein E-deficient mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 2.5.1.21 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17804677&form=6&db=m EP2306 [2-(4-biphenyl)-4-methyl-octahydro-1,4-benzoxazin-2-ol, hydrobromide], a novel squalene synthase inhibitor, reduces atherosclerosis in the cholesterol-fed rabbit. ongoing research,therapeutic application,unassigned 1,4,0 2.5.1.21 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20888243&form=6&db=m Design of more potent squalene synthase inhibitors with multiple activities. causal interaction,therapeutic application,unassigned 1,4,0 2.5.1.21 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24568631&form=6&db=m Design of Novel Potent Antihyperlipidemic Agents with Antioxidant/Anti-inflammatory Properties: Exploiting Phenothiazine's Strong Antioxidant Activity. therapeutic application,unassigned 4,0 2.5.1.21 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25061401&form=6&db=m Therapeutic approaches to drug targets in atherosclerosis. causal interaction,therapeutic application,unassigned 3,1,0 2.5.1.21 Atherosclerosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28728107&form=6&db=m Developing potential agents against atherosclerosis: Design, synthesis and pharmacological evaluation of novel dual inhibitors of oxidative stress and Squalene Synthase activity. causal interaction,therapeutic application,unassigned 1,4,0 2.5.1.21 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16909123&form=6&db=m Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Brain Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17634493&form=6&db=m Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. ongoing research,therapeutic application,unassigned 3,2,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11406540&form=6&db=m Potentiation of nitric oxide-induced apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor: implications in breast cancer. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12088116&form=6&db=m The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,4,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12442347&form=6&db=m Farnesyltransferase inhibitors in breast cancer therapy. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14613029&form=6&db=m Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,1,4 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15034210&form=6&db=m Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15535857&form=6&db=m New targets for therapy in breast cancer: farnesyltransferase inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15709195&form=6&db=m A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. causal interaction,ongoing research,therapeutic application,unassigned 2,4,4,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15996863&form=6&db=m Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. causal interaction,therapeutic application,unassigned 3,3,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16101130&form=6&db=m Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,3,4 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16769985&form=6&db=m Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,4,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16773203&form=6&db=m Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho. ongoing research,therapeutic application,unassigned 4,4,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17010069&form=6&db=m Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists. causal interaction,therapeutic application,unassigned 3,3,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17667598&form=6&db=m Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336). ongoing research,therapeutic application,unassigned 4,4,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17851757&form=6&db=m A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17876043&form=6&db=m The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo. ongoing research,therapeutic application,unassigned 4,1,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19153124&form=6&db=m Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20145184&form=6&db=m Tipifarnib plus tamoxifen in tamoxifen-resistant metastatic breast cancer: a negative phase II and screening of potential therapeutic markers by proteomic analysis. causal interaction,therapeutic application,unassigned 1,4,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21536547&form=6&db=m Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22547107&form=6&db=m A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103). ongoing research,therapeutic application,unassigned 2,4,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23164604&form=6&db=m Sasanquasaponin from Camellia oleifera Abel. induces cell cycle arrest and apoptosis in human breast cancer MCF-7 cells. causal interaction,ongoing research,therapeutic application,unassigned 2,4,4,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30106443&form=6&db=m Higenamine enhances the antitumor effects of cucurbitacin B in breast cancer by inhibiting the interaction of AKT and CDK2. causal interaction,unassigned 4,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31949508&form=6&db=m Experimental, Clinical and Morphological Analysis of H-Ras Oncoproteins for Locally Advanced Breast Cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33862663&form=6&db=m vHTS and 3D-QSAR for the Identification of Novel Phyto-inhibitors of Farnesyltransferase: Validation of Ascorbic Acid inhibition of Farnesyltransferase in an Animal Model of Breast Cancer. unassigned - 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33896802&form=6&db=m Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer. causal interaction,therapeutic application,unassigned 4,3,0 2.5.1.21 Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33983574&form=6&db=m Ras Signaling in Breast Cancer. therapeutic application,unassigned 4,0 2.5.1.21 Bronchiectasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29135627&form=6&db=m Quantitative Computed Tomography Metrics From the Transplanted Lung can Predict Forced Expiratory Volume in the First Second After Lung Transplantation. unassigned - 2.5.1.21 Burkitt Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8407887&form=6&db=m Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21ras CA1A2X peptidomimetics. ongoing research,unassigned 3,0 2.5.1.21 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8280377&form=6&db=m ras protein p21 processing enzyme farnesyltransferase in chemical carcinogen-induced murine skin tumors. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,1,1 2.5.1.21 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11520197&form=6&db=m Synthesis, molecular modeling, and structure-activity relationship of benzophenone-based CAAX-peptidomimetic farnesyltransferase inhibitors. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16143263&form=6&db=m Potent farnesyltransferase inhibitor ABT-100 abrogates acute allograft rejection. causal interaction,therapeutic application,unassigned 3,3,0 2.5.1.21 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18212005&form=6&db=m Functional polymorphisms in inbred rat strains and their allele frequencies in commercially available outbred stocks. diagnostic usage,unassigned 1,0 2.5.1.21 Carcinogenesis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24294361&form=6&db=m Potential biomarkers for paclitaxel sensitivity in hypopharynx cancer cell. unassigned - 2.5.1.21 Carcinoid Tumor http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31677963&form=6&db=m The diagnostic utility of zinc E-box 1 (ZEB1) transcription factor for identification of pulmonary sarcomatoid carcinoma in cytologic and surgical specimens. diagnostic usage,therapeutic application,unassigned 3,2,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7585182&form=6&db=m Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8407887&form=6&db=m Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21ras CA1A2X peptidomimetics. ongoing research,unassigned 3,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8607844&form=6&db=m Farnesyltransferase activity and mRNA expression in human skin basal cell carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9264581&form=6&db=m Expression of the farnesyltransferase beta-subunit gene in human ovarian carcinoma: correlation to K-ras mutation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9418856&form=6&db=m A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11739732&form=6&db=m Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. ongoing research,therapeutic application,unassigned 4,1,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12114424&form=6&db=m Suppression of rho B expression in invasive carcinoma from head and neck cancer patients. causal interaction,therapeutic application,unassigned 2,1,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12820305&form=6&db=m Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15609318&form=6&db=m Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration. ongoing research,therapeutic application,unassigned 3,1,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15994961&form=6&db=m Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16028213&form=6&db=m Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,4,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16166322&form=6&db=m Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17348444&form=6&db=m Expression of PTEN and FHIT is involved in regulating the balance between apoptosis and proliferation in lung carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18559769&form=6&db=m Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. causal interaction,ongoing research,therapeutic application,unassigned 3,1,3,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22549877&form=6&db=m Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-Kras(G12D) -LSL-Trp53(R172H) -Pdx1-Cre mice. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23557589&form=6&db=m Lipid synthesis and processing proteins ABHD5, PGRMC1 and squalene synthase can serve as novel immunohistochemical markers for sebaceous neoplasms and differentiate sebaceous carcinoma from sebaceoma and basal cell carcinoma with clear cell features. diagnostic usage,ongoing research,unassigned 3,1,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31677963&form=6&db=m The diagnostic utility of zinc E-box 1 (ZEB1) transcription factor for identification of pulmonary sarcomatoid carcinoma in cytologic and surgical specimens. diagnostic usage,therapeutic application,unassigned 3,2,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32314892&form=6&db=m [Effects of farnesyltransferase silencing on the migration and invasion of tongue squamous cell carcinoma]. ongoing research,unassigned 4,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32636318&form=6&db=m A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,4,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33307558&form=6&db=m Role of the Mevalonate Pathway in Adrenocortical Tumorigenesis. causal interaction,ongoing research,unassigned 3,1,0 2.5.1.21 Carcinoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34513998&form=6&db=m A New Survival Model Based on Cholesterol Biosynthesis-Related Genes for Prognostic Prediction in Clear Cell Renal Cell Carcinoma. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,1 2.5.1.21 Carcinoma, Basal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8607844&form=6&db=m Farnesyltransferase activity and mRNA expression in human skin basal cell carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,1 2.5.1.21 Carcinoma, Basal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23557589&form=6&db=m Lipid synthesis and processing proteins ABHD5, PGRMC1 and squalene synthase can serve as novel immunohistochemical markers for sebaceous neoplasms and differentiate sebaceous carcinoma from sebaceoma and basal cell carcinoma with clear cell features. diagnostic usage,ongoing research,unassigned 3,1,0 2.5.1.21 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1318747&form=6&db=m Subcellular localization of squalene synthase in human hepatoma cell line Hep G2. ongoing research,unassigned 4,0 2.5.1.21 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2538145&form=6&db=m Regulation of squalene synthetase in human hepatoma cell line Hep G2 by sterols, and not by mevalonate-derived non-sterols. ongoing research,unassigned 2,0 2.5.1.21 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8517861&form=6&db=m Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,1,0 2.5.1.21 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11846416&form=6&db=m A Link between cholesterol levels and phenobarbital induction of cytochromes P450. ongoing research,unassigned 1,0 2.5.1.21 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12452012&form=6&db=m [Correlation between inhibitory effect of Manumycin on human hepatoma cancer cell HepG2 and Ras signal transduction pathway] causal interaction,diagnostic usage,ongoing research,unassigned 1,3,4,0 2.5.1.21 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12735986&form=6&db=m Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors. ongoing research,unassigned 1,0 2.5.1.21 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12901918&form=6&db=m Syntheses of 3-ethylidenequinuclidine derivatives as squalene synthase inhibitors. Part 2: enzyme inhibition and effects on plasma lipid levels. ongoing research,therapeutic application,unassigned 1,1,0 2.5.1.21 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23164604&form=6&db=m Sasanquasaponin from Camellia oleifera Abel. induces cell cycle arrest and apoptosis in human breast cancer MCF-7 cells. causal interaction,ongoing research,therapeutic application,unassigned 2,4,4,0 2.5.1.21 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23924739&form=6&db=m ATF6? Stimulates Cholesterogenic Gene Expression and de Novo Cholesterol Synthesis. ongoing research,unassigned 3,0 2.5.1.21 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25473062&form=6&db=m Targeting Cellular Squalene Synthase, an Enzyme Essential for Cholesterol Biosynthesis, Is a Potential Antiviral Strategy against Hepatitis C Virus. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.5.1.21 Carcinoma, Hepatocellular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29732977&form=6&db=m Rational Discovery of Novel Squalene Synthase Inhibitors through Pharmacophore Modelling. ongoing research,unassigned 4,0 2.5.1.21 Carcinoma, Large Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17348444&form=6&db=m Expression of PTEN and FHIT is involved in regulating the balance between apoptosis and proliferation in lung carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 2.5.1.21 Carcinoma, Large Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31677963&form=6&db=m The diagnostic utility of zinc E-box 1 (ZEB1) transcription factor for identification of pulmonary sarcomatoid carcinoma in cytologic and surgical specimens. diagnostic usage,therapeutic application,unassigned 3,2,0 2.5.1.21 Carcinoma, Neuroendocrine http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31677963&form=6&db=m The diagnostic utility of zinc E-box 1 (ZEB1) transcription factor for identification of pulmonary sarcomatoid carcinoma in cytologic and surgical specimens. diagnostic usage,therapeutic application,unassigned 3,2,0 2.5.1.21 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12174342&form=6&db=m Farnesyltransferase inhibitors as radiation sensitizers. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,4,0 2.5.1.21 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14719076&form=6&db=m In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,4,0 2.5.1.21 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20554106&form=6&db=m Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Carcinoma, Non-Small-Cell Lung http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29765975&form=6&db=m Relationship of SNP rs2645429 in Farnesyl-Diphosphate Farnesyltransferase 1 Gene Promoter with Susceptibility to Lung Cancer. diagnostic usage,ongoing research,unassigned 3,3,0 2.5.1.21 Carcinoma, Ovarian Epithelial http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33744759&form=6&db=m Ubiquitin specific peptidase 32 acts as an oncogene in epithelial ovarian cancer by deubiquitylating farnesyl-diphosphate farnesyltransferase 1. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,2,0 2.5.1.21 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18559769&form=6&db=m Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. causal interaction,ongoing research,therapeutic application,unassigned 3,1,3,0 2.5.1.21 Carcinoma, Renal Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24993441&form=6&db=m BAI, a novel Cdk inhibitor, enhances farnesyltransferase inhibitor LB42708-mediated apoptosis in renal carcinoma cells through the downregulation of Bcl-2 and c-FLIP (L). causal interaction,therapeutic application,unassigned 1,4,0 2.5.1.21 Carcinoma, Small Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17348444&form=6&db=m Expression of PTEN and FHIT is involved in regulating the balance between apoptosis and proliferation in lung carcinomas. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,4,4,1 2.5.1.21 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15994961&form=6&db=m Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 2.5.1.21 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31677963&form=6&db=m The diagnostic utility of zinc E-box 1 (ZEB1) transcription factor for identification of pulmonary sarcomatoid carcinoma in cytologic and surgical specimens. diagnostic usage,therapeutic application,unassigned 3,2,0 2.5.1.21 Carcinoma, Squamous Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32314892&form=6&db=m [Effects of farnesyltransferase silencing on the migration and invasion of tongue squamous cell carcinoma]. ongoing research,unassigned 4,0 2.5.1.21 Cardiomyopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34374184&form=6&db=m Chemical Genetics Reveals a Role of Squalene Synthase in TGF? Signaling and Cardiomyogenesis. therapeutic application,unassigned 1,0 2.5.1.21 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10669567&form=6&db=m Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18838683&form=6&db=m A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. therapeutic application,unassigned 4,0 2.5.1.21 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19054015&form=6&db=m Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway. causal interaction,ongoing research,unassigned 4,2,0 2.5.1.21 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24582968&form=6&db=m Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Cardiovascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32557793&form=6&db=m New applications of squalene synthase inhibitors: Membrane cholesterol as a therapeutic target. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Cataract http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16440058&form=6&db=m Lanosterol synthase mutations cause cholesterol deficiency-associated cataracts in the Shumiya cataract rat. diagnostic usage,unassigned 3,0 2.5.1.21 Cataract http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31231834&form=6&db=m Lens cholesterol biosynthesis inhibition: A common mechanism of cataract formation in laboratory animals by pharmaceutical products. ongoing research,unassigned 1,0 2.5.1.21 Cataract http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33204712&form=6&db=m Identification of Differential Gene Expression Pattern in Lens Epithelial Cells Derived from Cataractous and Noncataractous Lenses of Shumiya Cataract Rat. causal interaction,unassigned 3,0 2.5.1.21 Cell Transformation, Neoplastic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10852640&form=6&db=m Pancreatic cancer: a review of emerging therapies. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Cell Transformation, Neoplastic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12662145&form=6&db=m Biotherapeutic approaches to pancreatic cancer. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Central Nervous System Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17634493&form=6&db=m Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. ongoing research,therapeutic application,unassigned 3,2,0 2.5.1.21 Chagas Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15215084&form=6&db=m In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Chagas Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15848765&form=6&db=m Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Chagas Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24789335&form=6&db=m Squalene synthase as a target for Chagas disease therapeutics. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,3,4 2.5.1.21 Chondrodysplasia Punctata http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11592808&form=6&db=m Genetic disorders of cholesterol biosynthesis in mice and humans. unassigned - 2.5.1.21 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10667232&form=6&db=m Cellular effects of a new farnesyltransferase inhibitor, RPR-115135, in a human isogenic colon cancer cell line model system HCT-116. ongoing research,therapeutic application,unassigned 4,3,0 2.5.1.21 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11251185&form=6&db=m RPR-115135, a new non peptidomimetic farnesyltransferase inhibitor, induces G0/G1 arrest only in serum starved cells. ongoing research,unassigned 4,0 2.5.1.21 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11507242&form=6&db=m Induction of micronuclei by a new non-peptidic mimetic farnesyltransferase inhibitor RPR-115135: role of gene mutations. ongoing research,unassigned 4,0 2.5.1.21 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11752120&form=6&db=m Nonpeptidomimetic farnesyltransferase inhibitor RPR-115135 increases cytotoxicity of 5-fluorouracil: role of p53. ongoing research,unassigned 4,0 2.5.1.21 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12115540&form=6&db=m RPR-115135, a farnesyltransferase inhibitor, increases 5-FU- cytotoxicity in ten human colon cancer cell lines: role of p53. ongoing research,therapeutic application,unassigned 3,1,0 2.5.1.21 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16925112&form=6&db=m In vitro and in vivo evaluation of two rational-designed nonpeptidic farnesyltransferase inhibitors on HT29 human colon cancer cell lines. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 2.5.1.21 Colonic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18097554&form=6&db=m Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rgammanull (NOG) mice. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,4,0 2.5.1.21 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12608469&form=6&db=m Increased farnesyltransferase activity in human colorectal cancer: relationship with clinicopathological features and K-ras mutation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 2.5.1.21 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16101154&form=6&db=m Biochemical changes of mevalonate pathway in human colorectal cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 2.5.1.21 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17460778&form=6&db=m Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,3,4 2.5.1.21 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17620438&form=6&db=m Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. ongoing research,therapeutic application,unassigned 1,1,0 2.5.1.21 Colorectal Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22753716&form=6&db=m A significant role of lipogenic enzymes in colorectal cancer. diagnostic usage,ongoing research,unassigned 1,4,0 2.5.1.21 Coronary Artery Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18587443&form=6&db=m Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.5.1.21 Craniosynostoses http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30617575&form=6&db=m Additional squamosal suture synostosis and segmented intracranial volume in patients with non-syndromic sagittal synostosis. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 2.5.1.21 Dehydration http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33270810&form=6&db=m CRISPR/Cas9-targeted mutagenesis of OsERA1 confers enhanced responses to abscisic acid and drought stress and increased primary root growth under nonstressed conditions in rice. causal interaction,therapeutic application,unassigned 1,1,0 2.5.1.21 Diphtheria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12483109&form=6&db=m Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Disorders of Excessive Somnolence http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33775088&form=6&db=m Relationship between overweight, obesity and sleep disorders in adolescents from selected cities of Upper Silesia, Poland. diagnostic usage,ongoing research,unassigned 1,1,0 2.5.1.21 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17169251&form=6&db=m Squalene synthase inhibition: a novel target for the management of dyslipidemia. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Dyslipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24568631&form=6&db=m Design of Novel Potent Antihyperlipidemic Agents with Antioxidant/Anti-inflammatory Properties: Exploiting Phenothiazine's Strong Antioxidant Activity. therapeutic application,unassigned 4,0 2.5.1.21 Endotoxemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20034462&form=6&db=m Farnesyltransferase inhibitor improved survival following endotoxin challenge in mice. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Erythema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21945151&form=6&db=m Exclusion of CTSB and FDFT1 as positional and functional candidate genes for keratolytic winter erythema (KWE). diagnostic usage,unassigned 2,0 2.5.1.21 Exanthema http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17004132&form=6&db=m L-NAME has opposite effects on the productions of S-adenosylhomocysteine and S-adenosylmethionine in V12-H-Ras and M-CR3B-Ras pheochromocytoma cells. ongoing research,unassigned 3,0 2.5.1.21 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11302335&form=6&db=m Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336. ongoing research,therapeutic application,unassigned 4,1,0 2.5.1.21 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14676133&form=6&db=m The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,3,0 2.5.1.21 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16818651&form=6&db=m HDJ-2 as a target for radiosensitization of glioblastoma multiforme cells by the farnesyltransferase inhibitor R115777 and the role of the p53/p21 pathway. therapeutic application,unassigned 2,0 2.5.1.21 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23566417&form=6&db=m ?v?3 Integrin and Fibroblast growth factor receptor 1 (FGFR1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma. causal interaction,ongoing research,therapeutic application,unassigned 1,4,3,0 2.5.1.21 Glioblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29198824&form=6&db=m Inhibition of Farnesyltransferase Potentiates NOTCH-Targeted Therapy against Glioblastoma Stem Cells. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7643114&form=6&db=m Selective inhibition of cholesterol biosynthesis in brain cells by squalestatin 1. diagnostic usage,ongoing research,unassigned 3,2,0 2.5.1.21 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10549939&form=6&db=m Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 2.5.1.21 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12115585&form=6&db=m Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation. ongoing research,therapeutic application,unassigned 4,2,0 2.5.1.21 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12127871&form=6&db=m Farnesyltransferase inhibitors: promises and realities. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14676133&form=6&db=m The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,3,0 2.5.1.21 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16170172&form=6&db=m Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,3,0 2.5.1.21 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16877733&form=6&db=m Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. ongoing research,therapeutic application,unassigned 2,4,0 2.5.1.21 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18417739&form=6&db=m Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. ongoing research,therapeutic application,unassigned 1,4,0 2.5.1.21 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19409983&form=6&db=m Manumycin inhibits STAT3, telomerase activity and growth of glioma cells by elevating intracellular reactive oxygen species generation. causal interaction,ongoing research,therapeutic application,unassigned 4,2,2,0 2.5.1.21 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21246394&form=6&db=m Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21339191&form=6&db=m Phase II trial of tipifarnib and radiation in children with newly diagnosed diffuse intrinsic pontine gliomas. ongoing research,therapeutic application,unassigned 4,4,0 2.5.1.21 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21556735&form=6&db=m Farnesyltransferase Inhibitor Manumycin Targets IL1?-Ras-HIF-1? Axis in Tumor Cells of Diverse Origin. causal interaction,ongoing research,therapeutic application,unassigned 2,4,2,0 2.5.1.21 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23633392&form=6&db=m Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Glioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25300619&form=6&db=m TGF-?-induced hCG-? regulates redox homeostasis in glioma cells. causal interaction,ongoing research,unassigned 3,1,0 2.5.1.21 Glomerulonephritis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18212005&form=6&db=m Functional polymorphisms in inbred rat strains and their allele frequencies in commercially available outbred stocks. diagnostic usage,unassigned 1,0 2.5.1.21 Head and Neck Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12006520&form=6&db=m A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,4,0 2.5.1.21 Head and Neck Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12174342&form=6&db=m Farnesyltransferase inhibitors as radiation sensitizers. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,4,0 2.5.1.21 Heart Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34374184&form=6&db=m Chemical Genetics Reveals a Role of Squalene Synthase in TGF? Signaling and Cardiomyogenesis. therapeutic application,unassigned 1,0 2.5.1.21 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12214289&form=6&db=m Myelodysplastic syndrome overview. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12214290&form=6&db=m Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12214292&form=6&db=m Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12447848&form=6&db=m Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12920034&form=6&db=m Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15485318&form=6&db=m Role of farnesyltransferase inhibitors in hematologic malignancies. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16556050&form=6&db=m Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17293017&form=6&db=m Farnesyltransferase inihibitors in hematologic malignancies. therapeutic application,unassigned 1,0 2.5.1.21 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17302532&form=6&db=m Clinical activity of tipifarnib in hematologic malignancies. therapeutic application,unassigned 4,0 2.5.1.21 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17882662&form=6&db=m Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18496498&form=6&db=m Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. causal interaction,therapeutic application,unassigned 2,3,0 2.5.1.21 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19530253&form=6&db=m Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models. causal interaction,therapeutic application,unassigned 1,4,0 2.5.1.21 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21083522&form=6&db=m Farnesyltransferase inhibitors: where are we now? causal interaction,therapeutic application,unassigned 4,3,0 2.5.1.21 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22209975&form=6&db=m Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells. therapeutic application,unassigned 4,0 2.5.1.21 Hematologic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27896224&form=6&db=m In Vitro Apoptotic Effects of Farnesyltransferase blockade in Acute Myeloid Leukemia Cells. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.5.1.21 Hepatitis C http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24690320&form=6&db=m Farnesyl-diphosphate farnesyltransferase 1 regulates hepatitis C virus propagation. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 2.5.1.21 Hepatitis C http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25473062&form=6&db=m Targeting Cellular Squalene Synthase, an Enzyme Essential for Cholesterol Biosynthesis, Is a Potential Antiviral Strategy against Hepatitis C Virus. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.5.1.21 Hepatitis C, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23870067&form=6&db=m Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C. causal interaction,diagnostic usage,unassigned 4,1,0 2.5.1.21 Hepatitis D http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33590450&form=6&db=m Lonafarnib: First Approval. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Hepatitis D, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30166948&form=6&db=m Current and Future Management of Chronic Hepatitis D. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Hepatitis, Autoimmune http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32251961&form=6&db=m The farnesyltransferase inhibitor tipifarnib protects against autoimmune hepatitis induced by Concanavalin A. therapeutic application,unassigned 4,0 2.5.1.21 Hyperalgesia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23442024&form=6&db=m Differential Effects of Subcutaneous Electrical Stimulation (SQS) and Transcutaneous Electrical Nerve Stimulation (TENS) in Rodent Models of Chronic Neuropathic or Inflammatory Pain. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15475176&form=6&db=m Lead nitrate-induced development of hypercholesterolemia in rats: sterol-independent gene regulation of hepatic enzymes responsible for cholesterol homeostasis. unassigned - 2.5.1.21 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16198340&form=6&db=m Antiproliferative and ultrastructural effects of BPQ-OH, a specific inhibitor of squalene synthase, on Leishmania amazonensis. therapeutic application,unassigned 4,0 2.5.1.21 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16741291&form=6&db=m Increased cholesterol biosynthesis and hypercholesterolemia in mice overexpressing squalene synthase in the liver. ongoing research,unassigned 3,0 2.5.1.21 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18167444&form=6&db=m Isolation and structural determination of squalene synthase inhibitor from Prunus mume fruit. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19054015&form=6&db=m Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway. causal interaction,ongoing research,unassigned 4,2,0 2.5.1.21 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19367148&form=6&db=m Pharmacologic inhibition of squalene synthase and other downstream enzymes of the cholesterol synthesis pathway: a new therapeutic approach to treatment of hypercholesterolemia. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21518985&form=6&db=m Lapaquistat acetate: development of a squalene synthase inhibitor for the treatment of hypercholesterolemia. causal interaction,therapeutic application,unassigned 1,4,0 2.5.1.21 Hypercholesterolemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21990243&form=6&db=m Potential role of nonstatin cholesterol lowering agents. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Hyperinsulinism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9112423&form=6&db=m Hyperinsulinemia potentiates activation of p21Ras by growth factors. ongoing research,unassigned 2,0 2.5.1.21 Hyperinsulinism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9751484&form=6&db=m Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells. unassigned - 2.5.1.21 Hyperinsulinism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9920764&form=6&db=m Effect of insulin on farnesyltransferase gene transcription and mRNA stability. causal interaction,unassigned 1,0 2.5.1.21 Hyperinsulinism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11440896&form=6&db=m Fetal hyperinsulinemia increases farnesylation of p21 Ras in fetal tissues. causal interaction,ongoing research,unassigned 2,4,0 2.5.1.21 Hyperinsulinism http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21668983&form=6&db=m Mechanism of the mitogenic influence of hyperinsulinemia. therapeutic application,unassigned 2,0 2.5.1.21 Hyperlactatemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28747716&form=6&db=m Burn-induced muscle metabolic derangements and mitochondrial dysfunction are associated with activation of HIF-1? and mTORC1: Role of protein farnesylation. causal interaction,therapeutic application,unassigned 1,1,0 2.5.1.21 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14735215&form=6&db=m Characteristics of the squalene synthase inhibitors produced by a Streptomyces species isolated from soils. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15044008&form=6&db=m Cholesterol diet-induced hyperlipidemia influences gene expression pattern of rat hearts: a DNA microarray study. therapeutic application,unassigned 1,0 2.5.1.21 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17002264&form=6&db=m Drug evaluation: TAK-475--an oral inhibitor of squalene synthase for hyperlipidemia. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24568631&form=6&db=m Design of Novel Potent Antihyperlipidemic Agents with Antioxidant/Anti-inflammatory Properties: Exploiting Phenothiazine's Strong Antioxidant Activity. therapeutic application,unassigned 4,0 2.5.1.21 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25392798&form=6&db=m Docking study of novel antihyperlipidemic thieno[2,3-d]pyrimidine; LM-1554, with some molecular targets related to hyperlipidemia - an investigation into its mechanism of action. unassigned - 2.5.1.21 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29710800&form=6&db=m Discovery of Potential Inhibitors of Squalene Synthase from Traditional Chinese Medicine Based on Virtual Screening and In Vitro Evaluation of Lipid-Lowering Effect. therapeutic application,unassigned 4,0 2.5.1.21 Hyperlipidemias http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31125877&form=6&db=m Evaluation of potential inhibitors of squalene synthase based on virtual screening and in vitro studies. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,4,0 2.5.1.21 Hyperlipoproteinemia Type II http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12679152&form=6&db=m Lipid-lowering effects of TAK-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. ongoing research,therapeutic application,unassigned 3,3,0 2.5.1.21 Hyperpigmentation http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30998907&form=6&db=m Automated in vivo screen in zebrafish identifies Clotrimazole as targeting a metabolic vulnerability in a melanoma model. ongoing research,therapeutic application,unassigned 1,4,0 2.5.1.21 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9765153&form=6&db=m Role of farnesyltransferase in ABA regulation of guard cell anion channels and plant water loss. therapeutic application,unassigned 1,0 2.5.1.21 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12119381&form=6&db=m Hypersensitivity of abscisic acid-induced cytosolic calcium increases in the Arabidopsis farnesyltransferase mutant era1-2. causal interaction,unassigned 2,0 2.5.1.21 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23442024&form=6&db=m Differential Effects of Subcutaneous Electrical Stimulation (SQS) and Transcutaneous Electrical Nerve Stimulation (TENS) in Rodent Models of Chronic Neuropathic or Inflammatory Pain. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Hypersensitivity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26703208&form=6&db=m Squalene is lipotoxic to yeast cells defective in lipid droplet biogenesis. unassigned - 2.5.1.21 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7542078&form=6&db=m Effect of limonene and sobrerol on monocrotaline-induced lung alterations and pulmonary hypertension. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 2.5.1.21 Hypertension, Pulmonary http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28395021&form=6&db=m Tipifarnib prevents development of hypoxia-induced pulmonary hypertension. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 2.5.1.21 Hypertrophy, Right Ventricular http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7542078&form=6&db=m Effect of limonene and sobrerol on monocrotaline-induced lung alterations and pulmonary hypertension. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 2.5.1.21 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7864626&form=6&db=m Expression, purification, and characterization of the human squalene synthase: use of yeast and baculoviral systems. ongoing research,therapeutic application,unassigned 4,1,0 2.5.1.21 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9300784&form=6&db=m Endotoxin, tumor necrosis factor, and interleukin-1 decrease hepatic squalene synthase activity, protein, and mRNA levels in Syrian hamsters. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,1 2.5.1.21 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24690320&form=6&db=m Farnesyl-diphosphate farnesyltransferase 1 regulates hepatitis C virus propagation. causal interaction,diagnostic usage,therapeutic application,unassigned 1,3,1,0 2.5.1.21 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29420769&form=6&db=m Lonafarnib synergizes with azoles against Aspergillus spp. and Exophiala spp. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31250536&form=6&db=m The farnesyltransferase ?-subunit RAM1 regulates localization of RAS proteins and appressorium-mediated infection in Magnaporthe oryzae. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31444903&form=6&db=m Quantitative Proteomic Analysis of Simian Primary Hepatocytes Reveals Candidate Molecular Markers for Permissiveness to Relapsing Malaria Plasmodium Cynomolgi. causal interaction,therapeutic application,unassigned 4,2,0 2.5.1.21 Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33590450&form=6&db=m Lonafarnib: First Approval. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19851749&form=6&db=m Mitogenic action of insulin: friend, foe or 'frenemy'? therapeutic application,unassigned 2,0 2.5.1.21 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21668983&form=6&db=m Mechanism of the mitogenic influence of hyperinsulinemia. therapeutic application,unassigned 2,0 2.5.1.21 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23275357&form=6&db=m The Association Between Hepatic Fat Content and Liver Injury in Obese Children and Adolescents: Effects of ethnicity, insulin resistance, and common gene variants. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,1,0 2.5.1.21 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25594415&form=6&db=m Role of protein farnesylation in burn-induced metabolic derangements and insulin resistance in mouse skeletal muscle. ongoing research,unassigned 4,0 2.5.1.21 Insulin Resistance http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28747716&form=6&db=m Burn-induced muscle metabolic derangements and mitochondrial dysfunction are associated with activation of HIF-1? and mTORC1: Role of protein farnesylation. causal interaction,therapeutic application,unassigned 1,1,0 2.5.1.21 Kidney Failure, Chronic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23672878&form=6&db=m Farnesyltransferase inhibitor R115777 protects against vascular disease in uremic mice. ongoing research,therapeutic application,unassigned 4,4,0 2.5.1.21 Laminopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23666920&form=6&db=m LMNA-associated cardiocutaneous progeria: an inherited autosomal dominant premature aging syndrome with late onset. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Laminopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33590450&form=6&db=m Lonafarnib: First Approval. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Leishmaniasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15848765&form=6&db=m Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10627474&form=6&db=m Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11369625&form=6&db=m Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. diagnostic usage,ongoing research,therapeutic application,unassigned 1,3,3,0 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11673687&form=6&db=m Current status of clinical trials of farnesyltransferase inhibitors. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12127871&form=6&db=m Farnesyltransferase inhibitors: promises and realities. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12214291&form=6&db=m Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias. causal interaction,therapeutic application,unassigned 2,3,0 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12447845&form=6&db=m Advancing the treatment of hematologic malignancies through the development of targeted interventions. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12447848&form=6&db=m Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15485318&form=6&db=m Role of farnesyltransferase inhibitors in hematologic malignancies. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15494423&form=6&db=m Farnesyltransferase inhibitors interact synergistically with the Chk1 inhibitor UCN-01 to induce apoptosis in human leukemia cells through interruption of both Akt and MEK/ERK pathways and activation of SEK1/JNK. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,3 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15744347&form=6&db=m Enhancement of manumycin A-induced apoptosis by methoxyamine in myeloid leukemia cells. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15750451&form=6&db=m Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia. therapeutic application,unassigned 2,0 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15896338&form=6&db=m Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18791165&form=6&db=m Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. therapeutic application,unassigned 2,0 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20071026&form=6&db=m Combination of tipifarnib and rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling pathways. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,4,0 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20126514&form=6&db=m Novel targeted drug therapies for the treatment of childhood acute leukemia. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21233404&form=6&db=m A phase I clinical-pharmacodynamic study of the farnesyltransferase inhibitor tipifarnib in combination with the proteasome inhibitor bortezomib in advanced acute leukemias. ongoing research,therapeutic application,unassigned 2,4,0 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23164604&form=6&db=m Sasanquasaponin from Camellia oleifera Abel. induces cell cycle arrest and apoptosis in human breast cancer MCF-7 cells. causal interaction,ongoing research,therapeutic application,unassigned 2,4,4,0 2.5.1.21 Leukemia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27137755&form=6&db=m Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1? and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro. ongoing research,therapeutic application,unassigned 2,3,0 2.5.1.21 Leukemia, Large Granular Lymphocytic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18791165&form=6&db=m Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling. therapeutic application,unassigned 2,0 2.5.1.21 Leukemia, Large Granular Lymphocytic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21983879&form=6&db=m Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. therapeutic application,unassigned 3,0 2.5.1.21 Leukemia, Lymphocytic, Chronic, B-Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15356656&form=6&db=m Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells. therapeutic application,unassigned 4,0 2.5.1.21 Leukemia, Myelogenous, Chronic, BCR-ABL Positive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12214288&form=6&db=m Chronic myeloid leukemia: current therapies and the potential role of farnesyltransferase inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Leukemia, Myelogenous, Chronic, BCR-ABL Positive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12714496&form=6&db=m Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,1,0 2.5.1.21 Leukemia, Myelogenous, Chronic, BCR-ABL Positive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17656006&form=6&db=m Cloning and characterization of a human BCR/ABL-positive cell line, K562/RR, resistant to the farnesyltransferase inhibition by tipifarnib. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 2.5.1.21 Leukemia, Myeloid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10498620&form=6&db=m In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 2.5.1.21 Leukemia, Myeloid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12886237&form=6&db=m Synergistic cytotoxic effects in myeloid leukemia cells upon cotreatment with farnesyltransferase and geranylgeranyl transferase-I inhibitors. causal interaction,therapeutic application,unassigned 2,3,0 2.5.1.21 Leukemia, Myeloid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20071026&form=6&db=m Combination of tipifarnib and rapamycin synergistically inhibits the growth of leukemia cells and overcomes resistance to tipifarnib via alteration of cellular signaling pathways. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,4,0 2.5.1.21 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12750696&form=6&db=m In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 2.5.1.21 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14556673&form=6&db=m Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15485318&form=6&db=m Role of farnesyltransferase inhibitors in hematologic malignancies. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15610664&form=6&db=m Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15820917&form=6&db=m [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia] causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17082323&form=6&db=m A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. ongoing research,therapeutic application,unassigned 3,4,0 2.5.1.21 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17351110&form=6&db=m A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. ongoing research,therapeutic application,unassigned 4,4,0 2.5.1.21 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17404110&form=6&db=m Identification of molecular predictors of response in a study of tipifarnib treatment in relapsed and refractory acute myelogenous leukemia. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,2 2.5.1.21 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18160667&form=6&db=m A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. therapeutic application,unassigned 4,0 2.5.1.21 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19109557&form=6&db=m Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. ongoing research,therapeutic application,unassigned 3,4,0 2.5.1.21 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19383813&form=6&db=m Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples. ongoing research,therapeutic application,unassigned 3,4,0 2.5.1.21 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20402600&form=6&db=m Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib. diagnostic usage,therapeutic application,unassigned 3,1,0 2.5.1.21 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20960519&form=6&db=m A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,4,0 2.5.1.21 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23996484&form=6&db=m Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. causal interaction,therapeutic application,unassigned 4,3,0 2.5.1.21 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24411921&form=6&db=m Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. ongoing research,therapeutic application,unassigned 3,4,0 2.5.1.21 Leukemia, Myeloid, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27896224&form=6&db=m In Vitro Apoptotic Effects of Farnesyltransferase blockade in Acute Myeloid Leukemia Cells. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.5.1.21 Leukemia, Myelomonocytic, Juvenile http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10627474&form=6&db=m Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyltransferase inhibitors. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Lipodystrophy http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29434718&form=6&db=m Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice. causal interaction,therapeutic application,unassigned 1,3,0 2.5.1.21 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24785259&form=6&db=m Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. unassigned - 2.5.1.21 Liver Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25755092&form=6&db=m Plasma cholesterol-lowering and transient liver dysfunction in mice lacking squalene synthase in the liver. ongoing research,unassigned 4,0 2.5.1.21 Liver Failure, Acute http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25046541&form=6&db=m Farnesyltransferase inhibitor, tipifarnib, prevents galactosamine/lipopolysaccharide-induced acute liver failure. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Liver Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12488548&form=6&db=m Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 2.5.1.21 Liver Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15930366&form=6&db=m Farnesyltransferase inhibitor, ABT-100, is a potent liver cancer chemopreventive agent. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.5.1.21 Liver Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22882915&form=6&db=m Expression of farnesyltransferase in primary liver cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 2.5.1.21 Liver Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32974183&form=6&db=m Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,4,0 2.5.1.21 Lung Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24582968&form=6&db=m Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Lung Injury http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7542078&form=6&db=m Effect of limonene and sobrerol on monocrotaline-induced lung alterations and pulmonary hypertension. causal interaction,ongoing research,therapeutic application,unassigned 3,2,4,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3610444&form=6&db=m Correlation between high salt intake and mortality rates for oesophageal and gastric cancers in Henan Province, China. diagnostic usage,unassigned 1,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11154688&form=6&db=m The farnesyltransferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 1,1,1,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12058275&form=6&db=m The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status. causal interaction,ongoing research,therapeutic application,unassigned 1,2,1,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12127871&form=6&db=m Farnesyltransferase inhibitors: promises and realities. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12174342&form=6&db=m Farnesyltransferase inhibitors as radiation sensitizers. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,4,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12867063&form=6&db=m An overview of farnesyltransferase inhibitors and their role in lung cancer therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=13679864&form=6&db=m Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14653878&form=6&db=m The role of farnesyltransferase inhibitors in lung cancer therapy. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14719076&form=6&db=m In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,4,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15467440&form=6&db=m The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt. causal interaction,diagnostic usage,ongoing research,unassigned 1,3,3,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15494604&form=6&db=m Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16145048&form=6&db=m Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17510428&form=6&db=m The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20554106&form=6&db=m Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23915247&form=6&db=m Combined p21-activated kinase and farnesyltransferase inhibitor treatment exhibits enhanced anti-proliferative activity on melanoma, colon and lung cancer cell lines. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25152164&form=6&db=m Squalene synthase induces tumor necrosis factor receptor 1 enrichment in lipid rafts to promote lung cancer metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29765975&form=6&db=m Relationship of SNP rs2645429 in Farnesyl-Diphosphate Farnesyltransferase 1 Gene Promoter with Susceptibility to Lung Cancer. diagnostic usage,ongoing research,unassigned 3,3,0 2.5.1.21 Lung Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32862200&form=6&db=m Squalene synthase promotes the invasion of lung cancer cells via the osteopontin/ERK pathway. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.5.1.21 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17639395&form=6&db=m Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 2.5.1.21 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19960345&form=6&db=m Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial. diagnostic usage,therapeutic application,unassigned 1,2,0 2.5.1.21 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21725056&form=6&db=m Multi-institutional phase II of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. ongoing research,therapeutic application,unassigned 4,3,0 2.5.1.21 Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23996484&form=6&db=m Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells. causal interaction,therapeutic application,unassigned 4,3,0 2.5.1.21 Lymphoma, B-Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19960345&form=6&db=m Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial. diagnostic usage,therapeutic application,unassigned 1,2,0 2.5.1.21 Lymphoma, Mantle-Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17639395&form=6&db=m Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 2.5.1.21 Lymphoma, Mantle-Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19960345&form=6&db=m Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial. diagnostic usage,therapeutic application,unassigned 1,2,0 2.5.1.21 Lymphoma, T-Cell http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32867592&form=6&db=m Roles of GTP and Rho GTPases in pancreatic islet beta cell function and dysfunction. unassigned - 2.5.1.21 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14695623&form=6&db=m Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo. causal interaction,therapeutic application,unassigned 1,3,0 2.5.1.21 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16007716&form=6&db=m Structurally simple farnesyltransferase inhibitors arrest the growth of malaria parasites. causal interaction,unassigned 3,0 2.5.1.21 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16970397&form=6&db=m Structurally simple, potent, Plasmodium selective farnesyltransferase inhibitors that arrest the growth of malaria parasites. therapeutic application,unassigned 4,0 2.5.1.21 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18198825&form=6&db=m 2-Oxotetrahydroquinoline-based antimalarials with high potency and metabolic stability. therapeutic application,unassigned 3,0 2.5.1.21 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18470859&form=6&db=m Development of benzophenone-based farnesyltransferase inhibitors as novel antimalarials. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18686940&form=6&db=m Potent, Plasmodium-selective farnesyltransferase inhibitors that arrest the growth of malaria parasites: structure-activity relationships of ethylenediamine-analogue scaffolds and homology model validation. unassigned - 2.5.1.21 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25963569&form=6&db=m The Recent Development of Farnesyltransferase Inhibitors as Anticancer and Antimalarial Agents. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26323840&form=6&db=m Effect of Farnesyltransferase Inhibitor R115777 on Mitochondria of Plasmodium falciparum. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Malaria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26887913&form=6&db=m Molecular dynamic simulations and structure-based pharmacophore development for farnesyltransferase inhibitors discovery. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 2.5.1.21 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9012455&form=6&db=m Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis. therapeutic application,unassigned 4,0 2.5.1.21 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23228035&form=6&db=m Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). diagnostic usage,ongoing research,therapeutic application,unassigned 3,2,4,0 2.5.1.21 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23915247&form=6&db=m Combined p21-activated kinase and farnesyltransferase inhibitor treatment exhibits enhanced anti-proliferative activity on melanoma, colon and lung cancer cell lines. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 2.5.1.21 Melanoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31005714&form=6&db=m Sasanquasaponin ??? from Schima crenata Korth induces autophagy through Akt/mTOR/p70S6K pathway and promotes apoptosis in human melanoma A375 cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 2.5.1.21 Mesothelioma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15756029&form=6&db=m Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.5.1.21 Mesothelioma, Malignant http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15756029&form=6&db=m Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.5.1.21 Metabolic Syndrome http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29434718&form=6&db=m Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice. causal interaction,therapeutic application,unassigned 1,3,0 2.5.1.21 Metabolism, Inborn Errors http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11592808&form=6&db=m Genetic disorders of cholesterol biosynthesis in mice and humans. unassigned - 2.5.1.21 Mevalonate Kinase Deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11592808&form=6&db=m Genetic disorders of cholesterol biosynthesis in mice and humans. unassigned - 2.5.1.21 mevalonate kinase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27652005&form=6&db=m Anti-inflammatory and cytoprotective effects of a squalene synthase inhibitor, TAK-475 active metabolite-I, in immune cells simulating mevalonate kinase deficiency (MKD)-like condition. ongoing research,ongoing research,therapeutic application,therapeutic application,unassigned,unassigned 4,4,3,3,0,0 2.5.1.21 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14581893&form=6&db=m Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14726402&form=6&db=m Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. causal interaction,diagnostic usage,therapeutic application,unassigned 3,3,1,0 2.5.1.21 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15728126&form=6&db=m Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. ongoing research,unassigned 1,0 2.5.1.21 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15958645&form=6&db=m The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 2.5.1.21 Multiple Myeloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17168661&form=6&db=m Farnesyltransferase inhibitors and rapamycin in the treatment of multiple myeloma. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Muscular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17599378&form=6&db=m Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 2.5.1.21 Mycoses http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21255433&form=6&db=m Synthetic arylquinuclidine derivatives exhibit antifungal activity against Candida albicans, Candida tropicalis and Candida parapsilopsis. therapeutic application,unassigned 4,0 2.5.1.21 Mycoses http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25809293&form=6&db=m Virus-induced gene silencing of Withania somnifera squalene synthase negatively regulates sterol and defence-related genes resulting in reduced withanolides and biotic stress tolerance. unassigned - 2.5.1.21 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12447845&form=6&db=m Advancing the treatment of hematologic malignancies through the development of targeted interventions. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 2.5.1.21 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12447848&form=6&db=m Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12947010&form=6&db=m Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. therapeutic application,unassigned 1,0 2.5.1.21 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14556673&form=6&db=m Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15865870&form=6&db=m Farnesyltransferase inhibitors in myelodysplastic syndrome. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17264294&form=6&db=m A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. ongoing research,therapeutic application,unassigned 2,4,0 2.5.1.21 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18410457&form=6&db=m Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18824842&form=6&db=m In vitro effects of the farnesyltransferase inhibitor tipifarnib on myelodysplastic syndrome progenitors. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,2,0 2.5.1.21 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20402600&form=6&db=m Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib. diagnostic usage,therapeutic application,unassigned 3,1,0 2.5.1.21 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20425327&form=6&db=m Farnesyltransferase inhibitors in myelodysplastic syndrome. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Myelodysplastic Syndromes http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20960519&form=6&db=m A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,4,0 2.5.1.21 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=2280101&form=6&db=m [Evaluation of ventricular arrhythmias late after coronary artery bypass graft surgery--relation to clinical variables] therapeutic application,unassigned 1,0 2.5.1.21 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18587443&form=6&db=m Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.5.1.21 Myocardial Infarction http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23897869&form=6&db=m Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. causal interaction,therapeutic application,unassigned 1,3,0 2.5.1.21 Myotoxicity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9221828&form=6&db=m Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Myotoxicity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15504460&form=6&db=m Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. therapeutic application,unassigned 2,0 2.5.1.21 Myotoxicity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17599378&form=6&db=m Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 2.5.1.21 Myotoxicity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29710800&form=6&db=m Discovery of Potential Inhibitors of Squalene Synthase from Traditional Chinese Medicine Based on Virtual Screening and In Vitro Evaluation of Lipid-Lowering Effect. therapeutic application,unassigned 4,0 2.5.1.21 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10852640&form=6&db=m Pancreatic cancer: a review of emerging therapies. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12662145&form=6&db=m Biotherapeutic approaches to pancreatic cancer. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14598891&form=6&db=m Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 2.5.1.21 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15647873&form=6&db=m Feasibility of CT scan-guided Tru-Cut serial liver biopsies to evaluate pharmacodynamic endpoints in patients with liver metastasis treated with experimental drugs. diagnostic usage,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15720261&form=6&db=m Novel anticancer targets and drug discovery in post genomic age. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,2,0 2.5.1.21 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18097554&form=6&db=m Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rgammanull (NOG) mice. diagnostic usage,ongoing research,therapeutic application,unassigned 3,4,4,0 2.5.1.21 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25152164&form=6&db=m Squalene synthase induces tumor necrosis factor receptor 1 enrichment in lipid rafts to promote lung cancer metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 2.5.1.21 Neoplasm Metastasis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32862200&form=6&db=m Squalene synthase promotes the invasion of lung cancer cells via the osteopontin/ERK pathway. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=1806189&form=6&db=m [Farnesyltransferase as target for non-cytotoxic anti-cancer agents: first steps] causal interaction,therapeutic application,unassigned 1,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3610444&form=6&db=m Correlation between high salt intake and mortality rates for oesophageal and gastric cancers in Henan Province, China. diagnostic usage,unassigned 1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7536929&form=6&db=m Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7671229&form=6&db=m Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8168127&form=6&db=m Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8280377&form=6&db=m ras protein p21 processing enzyme farnesyltransferase in chemical carcinogen-induced murine skin tumors. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,1,1 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8407887&form=6&db=m Potent inhibition of human tumor p21ras farnesyltransferase by A1A2-lacking p21ras CA1A2X peptidomimetics. ongoing research,unassigned 3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8878827&form=6&db=m Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9131250&form=6&db=m The potential of farnesyltransferase inhibitors as cancer chemotherapeutics. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9157972&form=6&db=m GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. causal interaction,unassigned 3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9264581&form=6&db=m Expression of the farnesyltransferase beta-subunit gene in human ovarian carcinoma: correlation to K-ras mutation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,1 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9294018&form=6&db=m Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras? therapeutic application,unassigned 4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9300784&form=6&db=m Endotoxin, tumor necrosis factor, and interleukin-1 decrease hepatic squalene synthase activity, protein, and mRNA levels in Syrian hamsters. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,1,2,1 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9315095&form=6&db=m Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,3,4 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9341167&form=6&db=m The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. ongoing research,therapeutic application,unassigned 4,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9418856&form=6&db=m A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9454897&form=6&db=m The farnesyltransferase inhibitor, FPT inhibitor III upregulates Bax and Bcl-xs expression and induces apoptosis in human ovarian cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9515813&form=6&db=m Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9525745&form=6&db=m Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,1,4,4 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9591188&form=6&db=m Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein farnesyltransferase. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9591189&form=6&db=m Chemopreventive effect of perillyl alcohol on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced tumorigenesis in (C3H/HeJ X A/J)F1 mouse lung. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9724732&form=6&db=m Farnesyltransferase inhibitors induce dramatic morphological changes of KNRK cells that are blocked by microtubule interfering agents. ongoing research,therapeutic application,unassigned 4,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9770500&form=6&db=m A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma. causal interaction,ongoing research,therapeutic application,unassigned 4,2,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9779989&form=6&db=m Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. causal interaction,therapeutic application,unassigned 2,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9860973&form=6&db=m Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9894422&form=6&db=m [Inhibitors of farnesyltransferase: a new approach for development of potential cancer drugs] causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10333174&form=6&db=m Assessment of the bioactive conformation of the farnesyltransferase protein binding recognition motif by computational methods. therapeutic application,unassigned 4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10370788&form=6&db=m Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units. ongoing research,therapeutic application,unassigned 4,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10382537&form=6&db=m Farnesyltransferase inhibitors: targeting the molecular basis of cancer. therapeutic application,unassigned 4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10471540&form=6&db=m Inhibition of human tumor cell growth in vitro and in vivo by a specific inhibitor of human farnesyltransferase: BIM-46068. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,1 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10498620&form=6&db=m In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10549939&form=6&db=m Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10554025&form=6&db=m Geranylgeranylated RhoB mediates suppression of human tumor cell growth by farnesyltransferase inhibitors. ongoing research,unassigned 1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10607742&form=6&db=m Effect of farnesyltransferase inhibitor FTI-276 on established lung adenomas from A/J mice induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10658533&form=6&db=m Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. causal interaction,ongoing research,therapeutic application,unassigned 2,4,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10658608&form=6&db=m Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10667235&form=6&db=m Farnesyltransferase inhibitor-induced regression of mammary tumors in TGF alpha and TGF alpha/neu transgenic mice correlates with inhibition of map kinase and p70s6 kinase phosphorylation. causal interaction,therapeutic application,unassigned 2,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10669567&form=6&db=m Successful virtual screening of a chemical database for farnesyltransferase inhibitor leads. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10712917&form=6&db=m Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects. causal interaction,unassigned 4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10770919&form=6&db=m Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10852640&form=6&db=m Pancreatic cancer: a review of emerging therapies. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10854950&form=6&db=m Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,3,1 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10871858&form=6&db=m Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. ongoing research,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10931682&form=6&db=m Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=10961860&form=6&db=m Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11093352&form=6&db=m Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11106157&form=6&db=m Successful molecular dynamics simulation of the zinc-bound farnesyltransferase using the cationic dummy atom approach. causal interaction,therapeutic application,unassigned 1,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11114730&form=6&db=m Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta. causal interaction,ongoing research,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11170866&form=6&db=m Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11173124&form=6&db=m Therapeutic targets in radiotherapy. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11195470&form=6&db=m Chemopreventive efficacy of promising farnesyltransferase inhibitors. ongoing research,therapeutic application,unassigned 2,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11267986&form=6&db=m Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11280800&form=6&db=m The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11398905&form=6&db=m Farnesyltransferase inhibitors: potential role in the treatment of cancer. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11406540&form=6&db=m Potentiation of nitric oxide-induced apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor: implications in breast cancer. causal interaction,ongoing research,therapeutic application,unassigned 1,4,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11426643&form=6&db=m Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11504474&form=6&db=m Targeting farnesyltransferase: is Ras relevant? causal interaction,therapeutic application,unassigned 1,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11520197&form=6&db=m Synthesis, molecular modeling, and structure-activity relationship of benzophenone-based CAAX-peptidomimetic farnesyltransferase inhibitors. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11673687&form=6&db=m Current status of clinical trials of farnesyltransferase inhibitors. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,2,4 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11706990&form=6&db=m Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 3,4,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11734111&form=6&db=m Evolving therapies: farnesyltransferase inhibitors. causal interaction,therapeutic application,unassigned 3,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11739732&form=6&db=m Absence of the CAAX endoprotease Rce1: effects on cell growth and transformation. ongoing research,therapeutic application,unassigned 4,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11741970&form=6&db=m RhoB, not RhoA, represses the transcription of the transforming growth factor beta type II receptor by a mechanism involving activator protein 1. causal interaction,unassigned 3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11809695&form=6&db=m Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. diagnostic usage,ongoing research,unassigned 3,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11842430&form=6&db=m Farnesylated proteins and cell cycle progression. ongoing research,therapeutic application,unassigned 4,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11929613&form=6&db=m The farnesyl transferase inhibitor RPR-130401 does not alter radiation susceptibility in human tumor cells with a K-Ras mutation in spite of large changes in ploidy and lamin B distribution. ongoing research,therapeutic application,unassigned 4,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12042705&form=6&db=m Ras processing as a therapeutic target in hematologic malignancies. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12174342&form=6&db=m Farnesyltransferase inhibitors as radiation sensitizers. diagnostic usage,ongoing research,therapeutic application,unassigned 1,1,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12214290&form=6&db=m Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12214291&form=6&db=m Farnesyltransferase inhibitors and myeloid malignancies: phase I evidence of Zarnestra activity in high-risk leukemias. causal interaction,therapeutic application,unassigned 2,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12441264&form=6&db=m Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. ongoing research,therapeutic application,unassigned 2,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12447845&form=6&db=m Advancing the treatment of hematologic malignancies through the development of targeted interventions. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12488548&form=6&db=m Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12490573&form=6&db=m c-myc down-regulation induces apoptosis in human cancer cell lines exposed to RPR-115135 (C31H29NO4), a non-peptidomimetic farnesyltransferase inhibitor. ongoing research,therapeutic application,unassigned 4,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12553057&form=6&db=m Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12592346&form=6&db=m The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. therapeutic application,unassigned 3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12608469&form=6&db=m Increased farnesyltransferase activity in human colorectal cancer: relationship with clinicopathological features and K-ras mutation. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,4,4 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12636885&form=6&db=m Inhibiting Ras signaling in the therapy of breast cancer. causal interaction,therapeutic application,unassigned 4,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12657282&form=6&db=m Aryl tetrahydropyridine inhibitors of farnesyltransferase: glycine, phenylalanine and histidine derivatives. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12657283&form=6&db=m Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12662145&form=6&db=m Biotherapeutic approaches to pancreatic cancer. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12738751&form=6&db=m Chemoprevention of benzo(a)pyrene-induced lung tumors in mice by the farnesyltransferase inhibitor R115777. causal interaction,ongoing research,therapeutic application,unassigned 4,2,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12882980&form=6&db=m High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors. unassigned - 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14581347&form=6&db=m A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies. diagnostic usage,ongoing research,therapeutic application,unassigned 2,2,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14592494&form=6&db=m Pyridone-containing farnesyltransferase inhibitors: synthesis and biological evaluation. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14598891&form=6&db=m Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14612973&form=6&db=m Manumycin induces apoptosis in human hepatocellular carcinoma HepG2 cells. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14653879&form=6&db=m Farnesyltransferase inhibitors: a promising future in cancer treatment. therapeutic application,unassigned 4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14695209&form=6&db=m Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14760509&form=6&db=m Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,2,2,4 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14763128&form=6&db=m Farnesyltransferase inhibitors as anticancer agents: current status. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=14981578&form=6&db=m Farnesyltransferase inhibitors. causal interaction,therapeutic application,unassigned 2,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15055985&form=6&db=m Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy? therapeutic application,unassigned 4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15069557&form=6&db=m Potentiated antitumor effects of a combination therapy with a farnesyltransferase inhibitor L-744,832 and butyrate in vitro. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15073096&form=6&db=m Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,2,4 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15124688&form=6&db=m Farnesyltransferase inhibitors (FTIs) in myeloid malignancies. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15131032&form=6&db=m Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. ongoing research,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15173010&form=6&db=m Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor models. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15389805&form=6&db=m Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,2,4,4 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15531395&form=6&db=m Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. therapeutic application,unassigned 4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15534083&form=6&db=m A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors. causal interaction,ongoing research,therapeutic application,unassigned 1,2,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15549191&form=6&db=m Radiation sensitization by inhibition of activated Ras. therapeutic application,unassigned 4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15610664&form=6&db=m Farnesyltransferase inhibitor therapy in acute myelogenous leukemia. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15611883&form=6&db=m Unraveling the mechanism of the farnesyltransferase enzyme. causal interaction,therapeutic application,unassigned 3,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15657509&form=6&db=m Synthesis, biodistribution and effects of farnesyltransferase inhibitor therapy on tumour uptake in mice of 99mTc labelled epidermal growth factor. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,3,4,4 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15659785&form=6&db=m Enhancement of tumor response by farnesyltransferase inhibitor in C3H/HeJ hepatocarcinoma. therapeutic application,unassigned 3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15710949&form=6&db=m Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. ongoing research,therapeutic application,unassigned 2,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15720261&form=6&db=m Novel anticancer targets and drug discovery in post genomic age. causal interaction,diagnostic usage,therapeutic application,unassigned 4,1,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15728126&form=6&db=m Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. ongoing research,unassigned 1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15756029&form=6&db=m Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15812228&form=6&db=m Enhancement of interleukin-12 gene-based tumor immunotherapy by the reduced secretion of p40 subunit and the combination with farnesyltransferase inhibitor. therapeutic application,unassigned 2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15865870&form=6&db=m Farnesyltransferase inhibitors in myelodysplastic syndrome. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15867362&form=6&db=m Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. unassigned - 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15930351&form=6&db=m Phase I study of the farnesyltransferase inhibitor BMS-214662 given weekly in patients with solid tumors. causal interaction,ongoing research,therapeutic application,unassigned 2,2,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15930366&form=6&db=m Farnesyltransferase inhibitor, ABT-100, is a potent liver cancer chemopreventive agent. causal interaction,ongoing research,therapeutic application,unassigned 3,4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15994961&form=6&db=m Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16101154&form=6&db=m Biochemical changes of mevalonate pathway in human colorectal cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,3,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16145048&form=6&db=m Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. causal interaction,diagnostic usage,ongoing research,unassigned 3,3,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16166322&form=6&db=m Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,4,4 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16222147&form=6&db=m A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies. causal interaction,therapeutic application,unassigned 1,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16230362&form=6&db=m Recent advances in understanding the antineoplastic mechanisms of farnesyltransferase inhibitors. causal interaction,therapeutic application,unassigned 4,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16251868&form=6&db=m Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours. diagnostic usage,ongoing research,therapeutic application,unassigned 1,2,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16362299&form=6&db=m Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors. causal interaction,diagnostic usage,therapeutic application,unassigned 3,2,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16403772&form=6&db=m Efficacy of the farnesyltransferase inhibitor R115777 in a rat mammary tumor model: role of Ha-ras mutations and use of microarray analysis in identifying potential targets. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16421428&form=6&db=m Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. ongoing research,therapeutic application,unassigned 2,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16769985&form=6&db=m Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. diagnostic usage,ongoing research,therapeutic application,unassigned 3,3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16909123&form=6&db=m Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16982767&form=6&db=m Anticancer Activity of BIM-46174, a New Inhibitor of the Heterotrimeric G{alpha}/G{beta}{gamma} Protein Complex. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17008695&form=6&db=m Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function. ongoing research,therapeutic application,unassigned 4,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17192846&form=6&db=m R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. causal interaction,ongoing research,therapeutic application,unassigned 1,1,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17255280&form=6&db=m Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors. causal interaction,ongoing research,therapeutic application,unassigned 1,3,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17411337&form=6&db=m Towards complete sets of farnesylated and geranylgeranylated proteins. causal interaction,therapeutic application,unassigned 2,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17483544&form=6&db=m Squalene synthase, a determinant of Raft-associated cholesterol and modulator of cancer cell proliferation. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17493934&form=6&db=m The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells. causal interaction,ongoing research,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17510428&form=6&db=m The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 3,2,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17585331&form=6&db=m Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17634493&form=6&db=m Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. ongoing research,therapeutic application,unassigned 3,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17639395&form=6&db=m Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma. causal interaction,ongoing research,therapeutic application,unassigned 3,3,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17882662&form=6&db=m Development of farnesyltransferase inhibitors for clinical cancer therapy: focus on hematologic malignancies. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17985347&form=6&db=m Reactive oxygen species-dependent destruction of MEK and Akt in Manumycin stimulated death of lymphoid tumor and myeloma cell lines. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18156496&form=6&db=m BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. ongoing research,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18237771&form=6&db=m Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,2 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18465885&form=6&db=m Computational Enzymatic Catalysis. causal interaction,therapeutic application,unassigned 3,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18496498&form=6&db=m Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib. causal interaction,therapeutic application,unassigned 2,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18708578&form=6&db=m Tumorigenic activity and therapeutic inhibition of Rheb GTPase. causal interaction,therapeutic application,unassigned 3,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18758974&form=6&db=m Farnesyltransferase inhibitors target multiple endothelial cell functions in angiogenesis. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18769123&form=6&db=m Autophagy induced by farnesyltransferase inhibitors in cancer cells. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18787409&form=6&db=m Translational control and cancer therapy. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18854983&form=6&db=m Combined effect of protein kinase B inhibitor or extracellular signal-regulated kinase inhibitor against farnesyltransferase inhibition-induced apoptosis in SiHa cells. ongoing research,therapeutic application,unassigned 4,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19153124&form=6&db=m Phase II trial of the farnesyltransferase inhibitor tipifarnib plus fulvestrant in hormone receptor-positive metastatic breast cancer: New York Cancer Consortium Trial P6205. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19515462&form=6&db=m 3D-QSAR with the aid of pharmacophore search and docking-based alignments for farnesyltransferase inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19530253&form=6&db=m Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models. causal interaction,therapeutic application,unassigned 1,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19878682&form=6&db=m Identification of novel peptide substrates for protein farnesyltransferase reveals two substrate classes with distinct sequence selectivities. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19903778&form=6&db=m Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. therapeutic application,unassigned 4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20074987&form=6&db=m Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase inhibitors in cancer therapy. therapeutic application,unassigned 4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20406854&form=6&db=m The Farnesyltransferase Inhibitor LB42708 Suppresses VEGF-induced Angiogenesis by Inhibiting Ras-dependent MAPK and PI3K/Akt Signal Pathways. causal interaction,ongoing research,therapeutic application,unassigned 1,1,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20425327&form=6&db=m Farnesyltransferase inhibitors in myelodysplastic syndrome. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20584014&form=6&db=m Enlarging the scope of cell-penetrating prenylated peptides to include farnesylated 'CAAX' box sequences and diverse cell types. causal interaction,therapeutic application,unassigned 4,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21246394&form=6&db=m Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21289252&form=6&db=m Inhibition of the Ras/Raf/MEK/ERK and RET Kinase Pathways with the Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Medullary and Differentiated Thyroid Malignancies. causal interaction,therapeutic application,unassigned 3,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21306898&form=6&db=m Synthesis and anti-migrative evaluation of moverastin derivatives. unassigned - 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21556735&form=6&db=m Farnesyltransferase Inhibitor Manumycin Targets IL1?-Ras-HIF-1? Axis in Tumor Cells of Diverse Origin. causal interaction,ongoing research,therapeutic application,unassigned 2,4,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21568272&form=6&db=m (--)-Xanthatin selectively induces GADD45? and stimulates caspase-independent cell death in human breast cancer MDA-MB-231 cells. ongoing research,therapeutic application,unassigned 4,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21599630&form=6&db=m Novel approaches to target pancreatic cancer. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22382068&form=6&db=m Inhibition of farnesyltransferase reduces angiogenesis by interrupting endothelial cell migration. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22546838&form=6&db=m Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22549877&form=6&db=m Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-Kras(G12D) -LSL-Trp53(R172H) -Pdx1-Cre mice. causal interaction,ongoing research,therapeutic application,unassigned 3,4,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22882915&form=6&db=m Expression of farnesyltransferase in primary liver cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,3,4 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23164604&form=6&db=m Sasanquasaponin from Camellia oleifera Abel. induces cell cycle arrest and apoptosis in human breast cancer MCF-7 cells. causal interaction,ongoing research,therapeutic application,unassigned 2,4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23557589&form=6&db=m Lipid synthesis and processing proteins ABHD5, PGRMC1 and squalene synthase can serve as novel immunohistochemical markers for sebaceous neoplasms and differentiate sebaceous carcinoma from sebaceoma and basal cell carcinoma with clear cell features. diagnostic usage,ongoing research,unassigned 3,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23915247&form=6&db=m Combined p21-activated kinase and farnesyltransferase inhibitor treatment exhibits enhanced anti-proliferative activity on melanoma, colon and lung cancer cell lines. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24059235&form=6&db=m Farnesyltransferase Inhibitors: A Comprehensive Review Based on Quantitative Structural Analysis. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24276257&form=6&db=m Virtual lead identification of farnesyltransferase inhibitors based on ligand and structure-based pharmacophore techniques. causal interaction,therapeutic application,unassigned 4,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24582968&form=6&db=m Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24587105&form=6&db=m Use of synthetic isoprenoids to target protein prenylation and Rho GTPases in breast cancer invasion. therapeutic application,unassigned 4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25152164&form=6&db=m Squalene synthase induces tumor necrosis factor receptor 1 enrichment in lipid rafts to promote lung cancer metastasis. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,4,3,4 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25424849&form=6&db=m Molecular Pathways: Targeting the Dependence of Mutant RAS Cancers on the DNA Damage Response. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25450772&form=6&db=m Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25963569&form=6&db=m The Recent Development of Farnesyltransferase Inhibitors as Anticancer and Antimalarial Agents. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26595770&form=6&db=m The noncoding RNAs SNORD50A and SNORD50B bind K-Ras and are recurrently deleted in human cancer. causal interaction,unassigned 3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26605548&form=6&db=m Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26706114&form=6&db=m 8-Hydroxyquinoline-based inhibitors of the Rce1 protease disrupt Ras membrane localization in human cells. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26887913&form=6&db=m Molecular dynamic simulations and structure-based pharmacophore development for farnesyltransferase inhibitors discovery. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26962870&form=6&db=m Stimulating Effect of Manumycin A on Suicidal Erythrocyte Death. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27137755&form=6&db=m Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1? and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro. ongoing research,therapeutic application,unassigned 2,3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27625053&form=6&db=m Sequential simulation (SqS) of clinical pathways: a tool for public and patient engagement in point-of-care diagnostics. diagnostic usage,unassigned 2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27630863&form=6&db=m Quantitative Gene Expression of ERG9 in Model Saccharomyces cerevisiae: Chamomile Extract For Human Cancer Treatment. causal interaction,therapeutic application,unassigned 4,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28445950&form=6&db=m The discovery of a novel compound with potent antitumor activity: virtual screening, synthesis, biological evaluation and preliminary mechanism study. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28556912&form=6&db=m Farnesyltransferase inhibitor FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29100957&form=6&db=m Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30108801&form=6&db=m New tricks for human farnesyltransferase inhibitor: cancer and beyond. causal interaction,diagnostic usage,ongoing research,therapeutic application 4,3,2,4 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30171497&form=6&db=m A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,2,3,4 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30271587&form=6&db=m Androgen-dependent alternative mRNA isoform expression in prostate cancer cells. causal interaction,unassigned 3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30337605&form=6&db=m MicroRNA induction by copy number gain is associated with poor outcome in squamous cell carcinoma of the lung. ongoing research,unassigned 4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30468409&form=6&db=m Characterization of farnesyl diphosphate farnesyl transferase 1 (FDFT1) expression in cancer. causal interaction,diagnostic usage,therapeutic application,unassigned 4,2,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31677963&form=6&db=m The diagnostic utility of zinc E-box 1 (ZEB1) transcription factor for identification of pulmonary sarcomatoid carcinoma in cytologic and surgical specimens. diagnostic usage,therapeutic application,unassigned 3,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32247731&form=6&db=m Ultrasounds-mediated 10-seconds synthesis of chalcones as potential farnesyltransferase inhibitors. diagnostic usage,ongoing research,therapeutic application,unassigned 1,4,1,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32308053&form=6&db=m An overview on natural farnesyltransferase inhibitors for efficient cancer therapy. causal interaction,therapeutic application,unassigned 1,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32313017&form=6&db=m Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1? pathway suppression. unassigned - 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32557793&form=6&db=m New applications of squalene synthase inhibitors: Membrane cholesterol as a therapeutic target. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32877662&form=6&db=m 20(S)-Rg3 upregulates FDFT1 via reducing miR-4425 to inhibit ovarian cancer progression. ongoing research,therapeutic application,unassigned 1,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32891861&form=6&db=m Indolizine-phenothiazine hybrids as the first dual inhibitors of tubulin polymerization and farnesyltransferase with synergistic antitumor activity. therapeutic application,unassigned 3,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32974183&form=6&db=m Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy. causal interaction,diagnostic usage,therapeutic application,unassigned 1,1,4,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33113804&form=6&db=m Roles of Farnesyl-Diphosphate Farnesyltransferase 1 in Tumour and Tumour Microenvironments. causal interaction,diagnostic usage,ongoing research,therapeutic application 3,4,1,4 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33305635&form=6&db=m Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on? ongoing research,therapeutic application,unassigned 1,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33744759&form=6&db=m Ubiquitin specific peptidase 32 acts as an oncogene in epithelial ovarian cancer by deubiquitylating farnesyl-diphosphate farnesyltransferase 1. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33773069&form=6&db=m Antitumor effects of low-dose tipifarnib on the mTOR signaling pathway and reactive oxygen species production in HIF-1?-expressing gastric cancer cells. causal interaction,therapeutic application,unassigned 4,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33792631&form=6&db=m Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells. ongoing research,therapeutic application,unassigned 2,2,0 2.5.1.21 Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34182690&form=6&db=m Design, Synthesis, and Evaluation of Novel Modular Bisubstrate Analogue Inhibitors of Farnesyltransferase. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neuralgia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23442024&form=6&db=m Differential Effects of Subcutaneous Electrical Stimulation (SQS) and Transcutaneous Electrical Nerve Stimulation (TENS) in Rodent Models of Chronic Neuropathic or Inflammatory Pain. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12553057&form=6&db=m Induction of N-myc in neuroblastoma by autocrine IGF-II depends on farnesylated Ras. Application of farnesyltransferase inhibitors. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12700894&form=6&db=m Farnesyltransferase inhibitor FTI-277 prevents autocrine growth stimulation of neuroblastoma by BDNF. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20053345&form=6&db=m 24S-hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury. ongoing research,unassigned 1,0 2.5.1.21 Neuroblastoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23643986&form=6&db=m Farnesyltransferase inhibitor attenuates methamphetamine toxicity-induced Ras proteins activation and cell death in neuroblastoma SH-SY5Y cells. causal interaction,ongoing research,unassigned 1,2,0 2.5.1.21 Neurofibroma, Plexiform http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16421428&form=6&db=m Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. ongoing research,therapeutic application,unassigned 2,4,0 2.5.1.21 Neurofibroma, Plexiform http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24500418&form=6&db=m Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. therapeutic application,unassigned 3,0 2.5.1.21 Neurofibromatoses http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7627966&form=6&db=m Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. causal interaction,therapeutic application,unassigned 3,3,0 2.5.1.21 Neurofibromatoses http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16421428&form=6&db=m Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. ongoing research,therapeutic application,unassigned 2,4,0 2.5.1.21 Neurofibromatoses http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24500418&form=6&db=m Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. therapeutic application,unassigned 3,0 2.5.1.21 Neurofibromatosis 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=7627966&form=6&db=m Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype. causal interaction,therapeutic application,unassigned 3,3,0 2.5.1.21 Neurofibromatosis 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16421428&form=6&db=m Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. ongoing research,therapeutic application,unassigned 2,4,0 2.5.1.21 Neurofibromatosis 1 http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24500418&form=6&db=m Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. therapeutic application,unassigned 3,0 2.5.1.21 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24785259&form=6&db=m Association of polymorphisms in GCKR and TRIB1 with nonalcoholic fatty liver disease and metabolic syndrome traits. unassigned - 2.5.1.21 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=25522307&form=6&db=m Association Study of Seven GWAS-Identified Common Variants with Nonalcoholic Fatty Liver Disease in Chinese Children. ongoing research,unassigned 1,0 2.5.1.21 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30889791&form=6&db=m The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. unassigned - 2.5.1.21 Non-alcoholic Fatty Liver Disease http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32827918&form=6&db=m Bavachinin inhibits cholesterol synthesis enzyme FDFT1 expression via AKT/mTOR/SREBP-2 pathway. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19245693&form=6&db=m Studies of CTNNBL1 and FDFT1 variants and measures of obesity: analyses of quantitative traits and case-control studies in 18,014 Danes. ongoing research,unassigned 1,0 2.5.1.21 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23620262&form=6&db=m Biological stereoselectivity of atropisomeric natural products and drugs. unassigned - 2.5.1.21 Obesity http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33775088&form=6&db=m Relationship between overweight, obesity and sleep disorders in adolescents from selected cities of Upper Silesia, Poland. diagnostic usage,ongoing research,unassigned 1,1,0 2.5.1.21 Obesity, Morbid http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19245693&form=6&db=m Studies of CTNNBL1 and FDFT1 variants and measures of obesity: analyses of quantitative traits and case-control studies in 18,014 Danes. ongoing research,unassigned 1,0 2.5.1.21 Osteoporosis, Postmenopausal http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33496154&form=6&db=m Association between FDFT1 gene polymorphism and postmenopausal osteoporosis. causal interaction,ongoing research,unassigned 1,4,0 2.5.1.21 Osteosarcoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20406948&form=6&db=m Driven to Death: Inhibition of Farnesylation Increases Ras Activity in Osteosarcoma and Promotes Growth Arrest and Cell Death. causal interaction,therapeutic application,unassigned 1,1,0 2.5.1.21 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9454897&form=6&db=m The farnesyltransferase inhibitor, FPT inhibitor III upregulates Bax and Bcl-xs expression and induces apoptosis in human ovarian cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.5.1.21 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9592196&form=6&db=m Involvement of caspase family proteases in FPT inhibitor III-induced apoptosis in human ovarian cancer cells. causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 2.5.1.21 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18237771&form=6&db=m Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,4,2 2.5.1.21 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22564713&form=6&db=m Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV. diagnostic usage,therapeutic application,unassigned 1,4,0 2.5.1.21 Ovarian Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=32877662&form=6&db=m 20(S)-Rg3 upregulates FDFT1 via reducing miR-4425 to inhibit ovarian cancer progression. ongoing research,therapeutic application,unassigned 1,2,0 2.5.1.21 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=19245693&form=6&db=m Studies of CTNNBL1 and FDFT1 variants and measures of obesity: analyses of quantitative traits and case-control studies in 18,014 Danes. ongoing research,unassigned 1,0 2.5.1.21 Overweight http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33775088&form=6&db=m Relationship between overweight, obesity and sleep disorders in adolescents from selected cities of Upper Silesia, Poland. diagnostic usage,ongoing research,unassigned 1,1,0 2.5.1.21 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=9361092&form=6&db=m Inhibition of growth and invasive activity of human pancreatic cancer cells by a farnesyltransferase inhibitor, manumycin. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 2.5.1.21 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11594773&form=6&db=m Requirement of c-jun N-terminal kinase for apoptotic cell death induced by farnesyltransferase inhibitor, farnesylamine, in human pancreatic cancer cells. ongoing research,unassigned 3,0 2.5.1.21 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11868368&form=6&db=m [Oleylamine (long-chain fatty amine)-induced cell death through MAP kinase pathways in human pancreatic cancer cells] causal interaction,ongoing research,therapeutic application,unassigned 1,3,4,0 2.5.1.21 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12420225&form=6&db=m Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2. ongoing research,therapeutic application,unassigned 3,1,0 2.5.1.21 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15084616&form=6&db=m Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. causal interaction,diagnostic usage,ongoing research,therapeutic application 1,3,1,3 2.5.1.21 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15328183&form=6&db=m A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer. diagnostic usage,ongoing research,therapeutic application,unassigned 4,3,4,0 2.5.1.21 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21599630&form=6&db=m Novel approaches to target pancreatic cancer. causal interaction,ongoing research,therapeutic application,unassigned 3,1,4,0 2.5.1.21 Pancreatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26352258&form=6&db=m Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. causal interaction,ongoing research,therapeutic application,unassigned 1,1,4,0 2.5.1.21 Pancreatitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24622074&form=6&db=m Farnesyltransferase regulates neutrophil recruitment and tissue damage in acute pancreatitis. causal interaction,ongoing research,unassigned 3,3,0 2.5.1.21 Papilloma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=8280377&form=6&db=m ras protein p21 processing enzyme farnesyltransferase in chemical carcinogen-induced murine skin tumors. causal interaction,diagnostic usage,ongoing research,therapeutic application 2,3,1,1 2.5.1.21 Parasitic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15848765&form=6&db=m Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Pheochromocytoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17004132&form=6&db=m L-NAME has opposite effects on the productions of S-adenosylhomocysteine and S-adenosylmethionine in V12-H-Ras and M-CR3B-Ras pheochromocytoma cells. ongoing research,unassigned 3,0 2.5.1.21 Pneumonia http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22949548&form=6&db=m Streptococcal M1 protein triggers farnesyltransferase-dependent formation of CXC chemokines in alveolar macrophages and neutrophil infiltration in the lung. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.5.1.21 Polycythemia Vera http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15632209&form=6&db=m Farnesyltransferase inhibitor tipifarnib (R115777) preferentially inhibits in vitro autonomous erythropoiesis of polycythemia vera patient cells. ongoing research,unassigned 2,0 2.5.1.21 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15860663&form=6&db=m Resistance to farnesyltransferase inhibitors in Bcr/Abl-positive lymphoblastic leukemia by increased expression of a novel ABC transporter homolog ATP11a. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17392819&form=6&db=m Increased resistance to a farnesyltransferase inhibitor by N-cadherin expression in Bcr/Abl-P190 lymphoblastic leukemia cells. causal interaction,ongoing research,therapeutic application,unassigned 1,4,1,0 2.5.1.21 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22399601&form=6&db=m Farnesyltransferase inhibitors: molecular evidence of therapeutic efficacy in acute lymphoblastic leukemia through cyclin d1 inhibition. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Precursor Cell Lymphoblastic Leukemia-Lymphoma http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22934254&form=6&db=m Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia. ongoing research,therapeutic application,unassigned 3,4,0 2.5.1.21 Primary Myelofibrosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12750696&form=6&db=m In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. causal interaction,ongoing research,therapeutic application,unassigned 3,2,3,0 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16126733&form=6&db=m Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. causal interaction,unassigned 2,0 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16862216&form=6&db=m A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. causal interaction,ongoing research,therapeutic application,unassigned 1,4,4,0 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18082640&form=6&db=m Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation. causal interaction,therapeutic application,unassigned 1,4,0 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18331619&form=6&db=m Increased mechanosensitivity and nuclear stiffness in Hutchinson-Gilford progeria cells: effects of farnesyltransferase inhibitors. causal interaction,therapeutic application,unassigned 1,1,0 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=18838683&form=6&db=m A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. therapeutic application,unassigned 4,0 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20074076&form=6&db=m Progeria, the nucleolus and farnesyltransferase inhibitors. therapeutic application,unassigned 4,0 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20526372&form=6&db=m Dynamics of lamin-A processing following precursor accumulation. therapeutic application,unassigned 4,0 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=20559568&form=6&db=m Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition. unassigned - 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21838864&form=6&db=m Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford Progeria syndrome cells. therapeutic application,unassigned 4,0 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23012407&form=6&db=m Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. ongoing research,therapeutic application,unassigned 2,4,0 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23475125&form=6&db=m Disruption of lamin B1 and lamin B2 processing and localization by farnesyltransferase inhibitors. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23897869&form=6&db=m Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. causal interaction,therapeutic application,unassigned 1,3,0 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26887913&form=6&db=m Molecular dynamic simulations and structure-based pharmacophore development for farnesyltransferase inhibitors discovery. causal interaction,diagnostic usage,therapeutic application,unassigned 3,1,4,0 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29029393&form=6&db=m Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29907918&form=6&db=m Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts. unassigned - 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=31411525&form=6&db=m Dysfunction of iPSC-derived endothelial cells in human Hutchinson-Gilford progeria syndrome. ongoing research,unassigned 3,0 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33590450&form=6&db=m Lonafarnib: First Approval. causal interaction,therapeutic application,unassigned 2,4,0 2.5.1.21 Progeria http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=34299092&form=6&db=m Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells. causal interaction,ongoing research,therapeutic application,unassigned 2,2,4,0 2.5.1.21 Prostatic Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22546838&form=6&db=m Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 2.5.1.21 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=17483544&form=6&db=m Squalene synthase, a determinant of Raft-associated cholesterol and modulator of cancer cell proliferation. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.5.1.21 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21299244&form=6&db=m Potent Farnesyltransferase Inhibitors with 1,4-Diazepane Scaffolds as Novel Destabilizing Microtubule Agents in Hormone-Resistant Prostate Cancer. causal interaction,therapeutic application,unassigned 3,4,0 2.5.1.21 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22546838&form=6&db=m Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer. causal interaction,diagnostic usage,ongoing research,unassigned 4,4,3,0 2.5.1.21 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=26605548&form=6&db=m Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies. causal interaction,diagnostic usage,therapeutic application,unassigned 1,4,1,0 2.5.1.21 Prostatic Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30271587&form=6&db=m Androgen-dependent alternative mRNA isoform expression in prostate cancer cells. causal interaction,unassigned 3,0 2.5.1.21 Pulmonary Disease, Chronic Obstructive http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=24582968&form=6&db=m Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. causal interaction,therapeutic application,unassigned 4,4,0 2.5.1.21 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=21873557&form=6&db=m Farnesyltransferase inhibitor, FTI-277, reduces mortality of septic mice along with improved bacterial clearance. ongoing research,unassigned 1,0 2.5.1.21 Sepsis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28556912&form=6&db=m Farnesyltransferase inhibitor FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation. causal interaction,ongoing research,therapeutic application,unassigned 4,4,4,0 2.5.1.21 Sexually Transmitted Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15996863&form=6&db=m Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. causal interaction,therapeutic application,unassigned 3,3,0 2.5.1.21 Sleep Initiation and Maintenance Disorders http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30373688&form=6&db=m A New Single-Item Sleep Quality Scale: Results of Psychometric Evaluation in Patients With Chronic Primary Insomnia and Depression. diagnostic usage,ongoing research,unassigned 4,2,0 2.5.1.21 squalene synthase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15009711&form=6&db=m Basis for abnormal desquamation and permeability barrier dysfunction in RXLI. causal interaction,therapeutic application,unassigned 3,1,0 2.5.1.21 squalene synthase deficiency http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=29909962&form=6&db=m Squalene Synthase Deficiency: Clinical, Biochemical, and Molecular Characterization of a Defect in Cholesterol Biosynthesis. causal interaction,unassigned 4,0 2.5.1.21 Squamous Cell Carcinoma of Head and Neck http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15994961&form=6&db=m Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells. causal interaction,ongoing research,therapeutic application,unassigned 4,1,4,0 2.5.1.21 Squamous Cell Carcinoma of Head and Neck http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33811046&form=6&db=m A Farnesyltransferase Inhibitor Shows Efficacy in HRAS-Mutant HNSCC. therapeutic application,unassigned 4,0 2.5.1.21 Stomach Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3610444&form=6&db=m Correlation between high salt intake and mortality rates for oesophageal and gastric cancers in Henan Province, China. diagnostic usage,unassigned 1,0 2.5.1.21 Streptococcal Infections http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=22949548&form=6&db=m Streptococcal M1 protein triggers farnesyltransferase-dependent formation of CXC chemokines in alveolar macrophages and neutrophil infiltration in the lung. causal interaction,ongoing research,therapeutic application,unassigned 4,3,4,0 2.5.1.21 Stroke http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23897869&form=6&db=m Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. causal interaction,therapeutic application,unassigned 1,3,0 2.5.1.21 Synostosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27438438&form=6&db=m The Significance of Squamosal Suture Synostosis. diagnostic usage,ongoing research,unassigned 4,3,0 2.5.1.21 Synostosis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30617575&form=6&db=m Additional squamosal suture synostosis and segmented intracranial volume in patients with non-syndromic sagittal synostosis. diagnostic usage,ongoing research,therapeutic application,unassigned 2,1,1,0 2.5.1.21 Synovitis http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=28123118&form=6&db=m Analysis of correlation and causes for discrepancy between quantitative and semi-quantitative Doppler scores in synovitis in rheumatoid arthritis. unassigned - 2.5.1.21 Tauopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=30918111&form=6&db=m A farnesyltransferase inhibitor activates lysosomes and reduces tau pathology in mice with tauopathy. ongoing research,therapeutic application,unassigned 3,4,0 2.5.1.21 Tauopathies http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=33677647&form=6&db=m Patterns of neuronal Rhes as a novel hallmark of tauopathies. causal interaction,therapeutic application,unassigned 2,1,0 2.5.1.21 Thyroid Carcinoma, Anaplastic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11297616&form=6&db=m Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. ongoing research,therapeutic application,unassigned 1,1,0 2.5.1.21 Thyroid Carcinoma, Anaplastic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11600533&form=6&db=m Cytochrome c release is upstream to activation of caspase-9, caspase-8, and caspase-3 in the enhanced apoptosis of anaplastic thyroid cancer cells induced by manumycin and paclitaxel. causal interaction,ongoing research,therapeutic application,unassigned 3,3,4,0 2.5.1.21 Thyroid Carcinoma, Anaplastic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=12574211&form=6&db=m p21 Waf-1 (Cip-1) enhances apoptosis induced by manumycin and paclitaxel in anaplastic thyroid cancer cells. ongoing research,therapeutic application,unassigned 1,2,0 2.5.1.21 Thyroid Carcinoma, Anaplastic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=15769983&form=6&db=m Bcl-2-associated X protein is the main mediator of manumycin a-induced apoptosis in anaplastic thyroid cancer cells. ongoing research,therapeutic application,unassigned 3,4,0 2.5.1.21 Thyroid Carcinoma, Anaplastic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16154259&form=6&db=m Combining a matrix metalloproteinase inhibitor, a farnesyltransferase inhibitor, and a taxane improves survival in an anaplastic thyroid cancer model. therapeutic application,unassigned 3,0 2.5.1.21 Thyroid Carcinoma, Anaplastic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16213899&form=6&db=m Modulation of parathyroid hormone-related protein levels (PTHrP) in anaplastic thyroid cancer. unassigned - 2.5.1.21 Thyroid Carcinoma, Anaplastic http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=16410725&form=6&db=m Redox Control of Manumycin A-Induced Apoptosis in Anaplastic Thyroid Cancer Cells: Involvement of the Xenobiotic Apoptotic Pathway. therapeutic application,unassigned 3,0 2.5.1.21 Triple Negative Breast Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=27137755&form=6&db=m Low-Dose Farnesyltransferase Inhibitor Suppresses HIF-1? and Snail Expression in Triple-Negative Breast Cancer MDA-MB-231 Cells In Vitro. ongoing research,therapeutic application,unassigned 2,3,0 2.5.1.21 Uterine Cervical Neoplasms http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=3610444&form=6&db=m Correlation between high salt intake and mortality rates for oesophageal and gastric cancers in Henan Province, China. diagnostic usage,unassigned 1,0 2.5.1.21 Vascular Diseases http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=23672878&form=6&db=m Farnesyltransferase inhibitor R115777 protects against vascular disease in uremic mice. ongoing research,therapeutic application,unassigned 4,4,0 2.5.1.21 Vitreoretinopathy, Proliferative http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?uid=11405068&form=6&db=m Role of inhibitors of isoprenylation in proliferation, phenotype and apoptosis of human retinal pigment epithelium. ongoing research,therapeutic application,unassigned 2,3,0